296 related articles for article (PubMed ID: 15074332)
1. Use of meglumine antimoniate in canine leishmaniasis.
Lamothe J
Vet Rec; 2004 Mar; 154(12):378. PubMed ID: 15074332
[No Abstract] [Full Text] [Related]
2. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
Moosavi Z; Nakhli A; Rassaii S
Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
[No Abstract] [Full Text] [Related]
3. Clinical follow-up examination after treatment of canine leishmaniasis.
Moritz A; Steuber S; Greiner M
Tokai J Exp Clin Med; 1998 Dec; 23(6):279-83. PubMed ID: 10622623
[TBL] [Abstract][Full Text] [Related]
4. [N-methyl glucamine antimoniate or Glucantime].
Rapp C; Simon F; Dordain ML
Med Trop (Mars); 2000; 60(4):342-3. PubMed ID: 11436584
[No Abstract] [Full Text] [Related]
5. Canine leishmaniasis chemotherapy: dog's clinical condition and risk of Leishmania transmission.
João A; Pereira MA; Cortes S; Santos-Gomes GM
J Vet Med A Physiol Pathol Clin Med; 2006 Dec; 53(10):540-5. PubMed ID: 17105576
[TBL] [Abstract][Full Text] [Related]
6. Characterization of circulating lymphocyte subpopulations in canine leishmaniasis throughout treatment with antimonials and allopurinol.
Miranda S; Martorell S; Costa M; Ferrer L; Ramis A
Vet Parasitol; 2007 Mar; 144(3-4):251-60. PubMed ID: 17110042
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children.
Layegh P; Pezeshkpoor F; Soruri AH; Naviafar P; Moghiman T
Am J Trop Med Hyg; 2009 Feb; 80(2):172-5. PubMed ID: 19190206
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis.
Salmanpour R; Razmavar MR; Abtahi N
Int J Dermatol; 2006 Sep; 45(9):1115-6. PubMed ID: 16961529
[No Abstract] [Full Text] [Related]
9. First report of the use of meglumine antimoniate for treatment of canine leishmaniasis in a pregnant dog.
Spada E; Proverbio D; Groppetti D; Perego R; Grieco V; Ferro E
J Am Anim Hosp Assoc; 2011; 47(1):67-71. PubMed ID: 21164165
[TBL] [Abstract][Full Text] [Related]
10. [Canine leishmaniasis in Spain: data for the clinician].
Ferrer L
Enferm Infecc Microbiol Clin; 1989; 7(6):293-5. PubMed ID: 2490443
[No Abstract] [Full Text] [Related]
11. Cutaneous lupoid leishmaniasis: a case report.
Ferahbaş A; Mistik S; Utaş S; Yaman O; Canoz O; Doganay M; Aşçioglu O
Cutis; 2006 Jan; 77(1):25-8; quiz 37-8. PubMed ID: 16475491
[TBL] [Abstract][Full Text] [Related]
12. Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate.
Vouldoukis I; Rougier S; Dugas B; Pino P; Mazier D; Woehrlé F
Vet Parasitol; 2006 Jan; 135(2):137-46. PubMed ID: 16242844
[TBL] [Abstract][Full Text] [Related]
13. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
Andersen EM; Cruz-Saldarriaga M; Llanos-Cuentas A; Luz-Cjuno M; Echevarria J; Miranda-Verastegui C; Colina O; Berman JD
Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of renal and hepatic functions in dogs naturally infected by visceral leishmaniasis submitted to treatment with meglumine antimoniate.
Ikeda-Garcia FA; Lopes RS; Ciarlini PC; Marques FJ; Lima VM; Perri SH; Feitosa MM
Res Vet Sci; 2007 Aug; 83(1):105-8. PubMed ID: 17150234
[TBL] [Abstract][Full Text] [Related]
15. Effects of antimonial therapy for canine leishmaniasis on antibody titer.
Amusategui I; Sainz A; Tesouro MA
Ann N Y Acad Sci; 1998 Jun; 849():444-6. PubMed ID: 9668509
[No Abstract] [Full Text] [Related]
16. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
Shazad B; Abbaszadeh B; Khamesipour A
Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of two different drug combinations for the treatment of canine leishmaniasis.
Pennisi MG; Lo Giudice S; Masucci M; De Majo M; Reale S; Vitale F
Vet Res Commun; 2008 Sep; 32 Suppl 1():S303-5. PubMed ID: 18683068
[No Abstract] [Full Text] [Related]
18. Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications.
Layegh P; Khademi Z; Afzal Aghaee M; Moghiman T
J Pediatric Infect Dis Soc; 2015 Dec; 4(4):356-8. PubMed ID: 26582874
[TBL] [Abstract][Full Text] [Related]
19. Real-time PCR assay in Leishmania-infected dogs treated with meglumine antimoniate and allopurinol.
Manna L; Reale S; Vitale F; Picillo E; Pavone LM; Gravino AE
Vet J; 2008 Aug; 177(2):279-82. PubMed ID: 17553711
[TBL] [Abstract][Full Text] [Related]
20. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
